Literature DB >> 24991346

Medicare part d and the federal employees health benefits program: a comparison of prescription drug coverage.

Annesha Lovett1.   

Abstract

BACKGROUND: There is much debate currently about how to restructure the Medicare program to achieve better value for the money. Many have cited the Federal Employees Health Benefits Program (FEHBP) as a model for reform.
OBJECTIVE: To compare drug coverage and cost-sharing between Medicare Part D and the FEHBP plans.
METHODS: A cross-sectional comparison was conducted of January 2009 data obtained from the Centers for Medicare & Medicaid Services, the Office of Personnel Management, and 3 health plan websites. Regression analysis and t-tests were used to examine drug coverage, copayment, and coinsurance amounts among Medicare Part D and FEHBP plans. The final study sample of Medicare Part D plans consisted of 19 formularies, covering 63% of total Part D enrollment. These 19 formularies represented 232 stand-alone prescription drug plans. In addition, 5 prescription drug plans or formularies in the FEHBP plans were included, which represents 70% of total FEHBP enrollment.
RESULTS: The results of this study reveal that formulary coverage of the top drugs dispensed and sold in the United States in 2009 ranged from 72% to 94% (average, 84%) in Medicare Part D plans and from 85% to 99% (average, 94%) in the FEHBP plans (P <.01). The mean copayment for generic drugs in Medicare Part D plans was $4.53 compared with a mean of $7.67 (P <.05) in the FEHBP plans. The difference between the 2 programs in mean copayment for brand-name drugs was nonsignificant. For generic drugs, the mean coinsurance rate was 17% for Medicare Part D plans and a mean of 20% for the FEHBP plans (P <.05).
CONCLUSIONS: This analysis shows that there are differences in prescription drug coverage and cost-sharing among plans within Medicare Part D and the FEHBP. To avoid extreme increases in payroll taxes and other revenues or major cutbacks in services, Medicare must explore ways to change the healthcare system to achieve better value for the money. The experience of the FEHBP suggests a possible means of accomplishing this objective.

Entities:  

Year:  2013        PMID: 24991346      PMCID: PMC4031701     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  14 in total

1.  An analysis of availability of Medicare+Choice, commercial HMO, and FEHBP plans in rural areas: implications for Medicare reform.

Authors:  Timothy McBride; Courtney Andrews; Keith Mueller; Michael Shambaugh-Miller
Journal:  Rural Policy Brief       Date:  2003-03-01

2.  The exclusion of benzodiazepine coverage in medicare: simple steps for avoiding a public health crisis.

Authors:  Kara Zivin Bambauer; James E Sabin; Stephen B Soumerai
Journal:  Psychiatr Serv       Date:  2005-09       Impact factor: 3.084

3.  Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.

Authors:  Jennifer Bowman; Amy Rousseau; David Silk; Catherine Harrison
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.

Authors:  Juliette Cubanski; Patricia Neuman
Journal:  Health Aff (Millwood)       Date:  2006-11-21       Impact factor: 6.301

5.  Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.

Authors:  Chien-Wen Tseng; Carol M Mangione; Robert H Brook; Emmett Keeler; R Adams Dudley
Journal:  JAMA       Date:  2007-06-20       Impact factor: 56.272

6.  The FEHBP as a model for a new Medicare program.

Authors:  S M Butler; R E Moffit
Journal:  Health Aff (Millwood)       Date:  1995       Impact factor: 6.301

7.  Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes.

Authors:  Becky A Briesacher; Stephen B Soumerai; Terry S Field; Hassan Fouayzi; Jerry H Gurwitz
Journal:  Arch Intern Med       Date:  2010-04-26

8.  Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.

Authors:  Hui-wen Keri Yang; Linda Simoni-Wastila; Ilene H Zuckerman; Bruce Stuart
Journal:  Psychiatr Serv       Date:  2008-04       Impact factor: 3.084

9.  Medicare Part D and nursing home residents.

Authors:  David G Stevenson; Haiden A Huskamp; Nancy L Keating; Joseph P Newhouse
Journal:  J Am Geriatr Soc       Date:  2007-07       Impact factor: 5.562

10.  Angiotensin receptor blockers on the formularies of Medicare drug plans.

Authors:  Walid F Gellad; Haiden A Huskamp; Kathryn A Phillips; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2007-05-15       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.